Sino Biopharmaceutical (SBMFF)
(Delayed Data from OTC)
$0.38 USD
0.00 (0.00%)
Updated Aug 19, 2024 12:12 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Balance Sheet
Fiscal Year End for Sino Biopharmaceutical falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | 2,261 | 1,974 |
Receivables | NA | NA | NA | 422 | 392 |
Notes Receivable | NA | NA | NA | 0 | 0 |
Inventories | NA | NA | NA | 272 | 240 |
Other Current Assets | NA | NA | NA | 348 | 999 |
Total Current Assets | NA | NA | NA | 3,303 | 3,605 |
Net Property & Equipment | NA | NA | NA | 996 | 1,000 |
Investments & Advances | NA | NA | NA | 1,625 | 374 |
Other Non-Current Assets | NA | NA | NA | 0 | 0 |
Deferred Charges | NA | NA | NA | 67 | 84 |
Intangibles | NA | NA | NA | 147 | 3,126 |
Deposits & Other Assets | NA | NA | NA | 483 | 60 |
Total Assets | NA | NA | NA | 6,841 | 8,436 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | 0 | 0 |
Accounts Payable | NA | NA | NA | 282 | 262 |
Current Portion Long-Term Debt | NA | NA | NA | 225 | 96 |
Current Portion Capital Leases | NA | NA | NA | 0 | 0 |
Accrued Expenses | NA | NA | NA | 0 | 0 |
Income Taxes Payable | NA | NA | NA | 9 | 27 |
Other Current Liabilities | NA | NA | NA | 1,066 | 786 |
Total Current Liabilities | NA | NA | NA | 1,586 | 1,175 |
Mortgages | NA | NA | NA | 0 | 0 |
Deferred Taxes/Income | NA | NA | NA | 113 | 284 |
Convertible Debt | NA | NA | NA | 852 | 0 |
Long-Term Debt | NA | NA | NA | 1,003 | 1,141 |
Non-Current Capital Leases | NA | NA | NA | 0 | 0 |
Other Non-Current Liabilities | NA | NA | NA | 0 | 0 |
Minority Interest (Liabilities) | NA | NA | NA | 0 | 0 |
Total Liabilities | NA | NA | NA | 3,592 | 2,607 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | 0 | 0 |
Common Stock (Par) | NA | NA | NA | 60 | 40 |
Capital Surplus | NA | NA | NA | 457 | 1,823 |
Retained Earnings | NA | NA | NA | 1,517 | 2,252 |
Other Equity | NA | NA | NA | 1,283 | 1,774 |
Treasury Stock | NA | NA | NA | 68 | 60 |
Total Shareholder's Equity | NA | NA | NA | 3,249 | 5,829 |
Total Liabilities & Shareholder's Equity | NA | NA | NA | 6,841 | 8,436 |
Total Common Equity | 0 | 0 | 0 | 3,249 | 5,829 |
Shares Outstanding | 18,813.80 | 18,813.80 | NA | 18,882.40 | 18,882.40 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.17 | 0.31 |
Fiscal Year End for Sino Biopharmaceutical falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | -99,999 | -99,999 |
Receivables | NA | NA | NA | NA | NA |
Notes Receivable | NA | NA | NA | NA | NA |
Inventories | NA | NA | NA | NA | NA |
Other Current Assets | NA | NA | NA | NA | NA |
Total Current Assets | NA | NA | NA | NA | NA |
Net Property & Equipment | NA | NA | NA | NA | NA |
Investments & Advances | NA | NA | NA | NA | NA |
Other Non-Current Assets | NA | NA | NA | NA | NA |
Deferred Charges | NA | NA | NA | NA | NA |
Intangibles | NA | NA | NA | NA | NA |
Deposits & Other Assets | NA | NA | NA | NA | NA |
Total Assets | NA | NA | NA | NA | NA |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | NA | NA |
Accounts Payable | NA | NA | NA | NA | NA |
Current Portion Long-Term Debt | NA | NA | NA | NA | NA |
Current Portion Capital Leases | NA | NA | NA | NA | NA |
Accrued Expenses | NA | NA | NA | NA | NA |
Income Taxes Payable | NA | NA | NA | NA | NA |
Other Current Liabilities | NA | NA | NA | NA | NA |
Total Current Liabilities | NA | NA | NA | NA | NA |
Mortgages | NA | NA | NA | NA | NA |
Deferred Taxes/Income | NA | NA | NA | NA | NA |
Convertible Debt | NA | NA | NA | NA | NA |
Long-Term Debt | NA | NA | NA | NA | NA |
Non-Current Capital Leases | NA | NA | NA | NA | NA |
Other Non-Current Liabilities | NA | NA | NA | NA | |
Minority Interest (Liabilities) | NA | NA | NA | NA | NA |
Total Liabilities | NA | NA | NA | NA | NA |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | NA | NA |
Common Stock (Par) | NA | NA | NA | NA | NA |
Capital Surplus | NA | NA | NA | NA | NA |
Retained Earnings | NA | NA | NA | NA | NA |
Other Equity | NA | NA | NA | NA | NA |
Treasury Stock | NA | NA | NA | NA | NA |
Total Shareholder's Equity | NA | NA | NA | NA | NA |
Total Liabilities & Shareholder's Equity | NA | NA | NA | NA | NA |
Total Common Equity | 0 | 0 | 0 | 0 | 0 |
Shares Outstanding | 18,791.20 | 18,813.80 | 18,813.80 | 18,813.80 | 18,813.80 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |